Company
Headquarters: Zhubei, Taiwan
CEO: Mr. Alvin Lin
TW$1.29 Billion
TWD as of Jan. 1, 2024
US$42.2 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $192.67 B |
| Stryker Corporation | $113.24 B |
| Medtronic | $111.60 B |
| Boston Scientific Corporation | $85.22 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $49.33 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Taiwan Biomaterial Co., Ltd. develops and sells medical devices in Taiwan. The company provides Foamagen, an absorbable biomaterial for dura reconstruction after surgeries; stroke interventional treatment devices; and devices for the treatment of early degenerative arthritis, and tissue repair and regeneration. Taiwan Biomaterial Co., Ltd. is based in Zhubei, Taiwan.
Top 1-year algo backtest: +269.94%
$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Taiwan Biomaterial Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6649 wb_incandescent